Journal article

Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment

Theodore WK Ng, Esther MM Ooi, Gerald F Watts, Dick C Chan, Peter J Meikle, P Hugh R Barrett

The Journal of Clinical Endocrinology & Metabolism | ENDOCRINE SOC | Published : 2015

Abstract

INTRODUCTION: The objective of the study was to examine post hoc associations between plasma sphingolipids and lipoprotein kinetics in men with the metabolic syndrome after rosuvastatin treatment. MATERIALS AND METHODS: Plasma sphingolipid profiling, determined by tandem mass spectrometry, was performed in a randomized, double-blind, triple-crossover trial (n = 12) of 5-week treatment periods with placebo or rosuvastatin (10 or 40 mg/d) with 2-week washouts between treatments. RESULTS AND DISCUSSION: Baseline plasma ceramides were associated with very low-density lipoprotein (VLDL) apolipoprotein (apo)-B-100 concentration (r = 0.58, P < .05) and inversely with VLDL apoB-100 fractional catabo..

View full abstract

Grants

Funding Acknowledgements

This work was supported by grants and fellowships from the National Health Foundation of Australia, the National Health and Medical Research Council of Australia, the Medical Research Fund of the Royal Perth Hospital, the OIS Program of the Victorian Government, AstraZeneca Pty Ltd Australia, and Pfizer Australia. T.W.K.N. and E.M.M.O. are National Health and Medical Research Council Postdoctoral Research Fellows. D.C.C. is a Career Development Fellow of the National Health and Medical Research Council. P.J.M. and P.H.R.B. are National Health and Medical Research Council Senior Research Fellows.